Financial Performance - The company's reported net sales reached $5061 billion, demonstrating a 228% increase year-over-year[21] - Operational net sales grew by 216% year-over-year[14] - Organic net sales increased by 174% compared to the previous year[14] - Reported earnings per share (EPS) stood at $053, compared to $022 in Q2 2024[18] - Adjusted EPS was $075, up from $062 in Q2 2024[18] - The company's free cash flow reached $1129 million in Q2 2025, compared to $660 million in Q2 2024[35] Segment Performance - MedSurg segment reported net sales of $1716 billion, a 157% increase year-over-year[22] - Cardiovascular segment reported net sales of $3345 billion, a 268% increase year-over-year[25] - Cardiology segment net sales increased by 293% to $2647 billion[27] - Electrophysiology (EP) net sales surged by 961% to $840 million[27] Guidance - The company projects Q3 2025 reported net sales growth of 17%-19% and organic net sales growth of 12%-14%[18] - Q3 2025 reported EPS is expected to be $044-$046, with adjusted EPS of $070-$072[18] - For the full year 2025, the company anticipates reported net sales growth of 18%-19% and organic net sales growth of 14%-15%[18] - Full year 2025 reported EPS is projected to be $189-$193, with adjusted EPS of $295-$299[18]

Core Insights - Boston Scientific Corporation reported net sales of $5.061 billion for Q2 2025, representing a growth of 22.8% on a reported basis, 21.6% on an operational basis, and 17.4% on an organic basis compared to the previous year [1][7][10] - The company achieved a GAAP net income of $797 million, or $0.53 per share, compared to $324 million, or $0.22 per share, a year ago, with adjusted EPS of $0.75 compared to $0.62 a year ago [1][7][10] Financial Performance - The second quarter financial results showed significant growth across various segments, with MedSurg growing by 15.7% reported, Cardiovascular by 26.8% reported, and Urology by 28.9% reported [6][7] - The net sales growth by region included a 30.7% increase in the U.S., 6.8% in EMEA, 18.0% in APAC, and 11.6% in Emerging Markets [7][8] Strategic Developments - The company received FDA approval to expand the use of the FARAPULSE™ Pulsed Field Ablation System for treating drug refractory, symptomatic persistent atrial fibrillation [7] - Boston Scientific commenced enrollment in the ReMATCH IDE clinical trial for evaluating the FARAWAVE™ and FARAPOINT™ PFA Catheters [7] - The company completed acquisitions of Intera Oncology® Inc. and SoniVie Ltd., enhancing its product offerings in the medical device sector [7] Guidance - For the full year 2025, Boston Scientific estimates net sales growth of approximately 18% to 19% on a reported basis and 14% to 15% on an organic basis [10][11] - The company projects GAAP EPS in the range of $1.89 to $1.93 and adjusted EPS of $2.95 to $2.99 for the full year [10][11]

The FDA approval for expanded labeling was supported by clinical evidence from phase one of the ADVANTAGE AF clinical trial presented at AF Symposium 2025 and recently published in the Journal of the American College of Cardiology and met both the primary safety and effectiveness endpoints. In the prospective, single-arm trial, 260 patients who were drug intolerant to at least one Class I/III anti-arrhythmic drug (AAD) were enrolled at 43 global sites. There were no reported incidences of stroke, pulmonary ...